Genmab — Marts 2021
-
DNB har vendt 180 grader og anbefaler nu "køb" af Genmab mod tidligere "sælg". Kursmålet er samtidig hævet til 2360 kr. fra 2250 kr., viser data fra Bloomberg News
-
Genmab/Bofa: Løfter anbefaling til "køb"
https://www.proinvestor.com/investornyt/673099/genmab-bofa-lofter-anbefaling-til-kob -
Well, er det ikke mere et spørgsmål om, at kursen er faldet så meget, at uændrede kursmål nu skal give “køb” anbefalinger?
-
the TGA in Australia APPROVES A NEW MEDICATION FOR MS: OFATUMUMAB https://msra.org.au/news/tga-approves-ofatumumab/
-
That also brought a smile to my face
-
Funny there’s no more excitement about the pdufa on tiso... This is the first program with GEN ownership coming through the pipes. Finally (and hopefully), we will get some return for the many, many, many funds we’ve been throwing at the pipeline
-
27 days and counting down
-
Aktier/åbning: C25 fortsætter de grønne takter med Bavarian/Novo og Genmab https://www.proinvestor.com/investornyt/673102/aktier-abning-c25-fortsaetter-de-gronne-takter-med-bavarian-i-front
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind